Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gastrointestinal Cancers
•
Medical Oncology
In clearly resectable pancreatic adenocarcinoma with no arterial or venous involvement, is there a role for neoadjuvant chemotherapy?
Would location, i.e. body/tail vs head of pancreas, impact this decision?
Related Questions
How do you choose between Atezolizumab/Bevacizumab (IMbrave 150) versus Durvalumab/Tremelimumab (HIMALAYA) in first-line metastatic hepatocellular cancer?
Do you try to incorporate mFOLFIRINOX in total neoadjuvant therapy for rectal cancer?
Are durva/cis/gem or pembro/cis/gem less efficacious in cholangiocarcinomas with FGFR2 fusions?
Do you offer a curative surgery (Whipple procedure) to patients with duodenal adenocarcinoma, with 2-5 liver metastases, and with near CR after 3-6 months of FOLFOX chemotherapy?
For a patient with a lung tumor that is radiographically consistent with early-stage NSCLC but pathology with characteristics overlapping with upper GI origin, what additional diagnostic procedures would you consider before treating?
What are your top takeaways in GI Cancers from ASCO 2023?
How would you approach an MSI-H HPV+ T2 N1 squamous cell carcinoma of the anus?
How would you sequence treatment of a synchronous IC1 high-grade serous ovarian cancer and cT3N1 rectal cancer?
How do you counsel patients and partners of patients with HPV+ cancers regarding the HPV vaccine?
How would you treat a synchronous low rectal adenocarcinoma and anal squamous cell carcinoma with involved pelvic and inguinal nodes?